(Q43015031)

12 November 2017

0 references

Metformin and cancer: licence to heal? (English)

1 reference

12 November 2017

1 reference

Dimitri P Mikhailidis

series ordinal

3

object named as

Dimitri P Mikhailidis

1 reference

12 November 2017

Nikolaos Papanas

1

1 reference

PubMed ID

20557275

12 November 2017

Efstratios Maltezos

series ordinal

2

1 reference

PubMed ID

20557275

12 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Investigational Drugs

12 November 2017

1 reference

12 November 2017

19

1 reference

12 November 2017

8

1 reference

12 November 2017

913-917

1 reference

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

12 November 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Diabetes mellitus and risk of breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Diabetes mellitus and risk of bladder cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Obesity and cancer risk: the role of the insulin-IGF axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Sulphonylureas and cancer: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Does diabetes therapy influence the risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Mitogenic action of insulin: friend, foe or 'frenemy'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin in breast cancer: time for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin as an addition to conventional chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin inhibits inflammatory angiogenesis in a murine sponge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

Metformin: diamonds are forever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499122

10.1517/13543784.2010.499122

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

20557275